IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 6.25
(-12.22%)
SEK 6.25
(-12.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -173.32 Million SEK | -62.3% |
| 2022 | -109.12 Million SEK | -294.75% |
| 2021 | 55.36 Million SEK | 162.36% |
| 2020 | -89.46 Million SEK | 4.07% |
| 2019 | -93.17 Million SEK | -28.15% |
| 2018 | -72.56 Million SEK | -32.1% |
| 2017 | -53.87 Million SEK | -20.11% |
| 2016 | -45.73 Million SEK | -67.81% |
| 2015 | -27.3 Million SEK | -442.04% |
| 2014 | -14.11 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -8.36 Million SEK | 90.41% |
| 2024 Q3 | -27.56 Million SEK | -703.59% |
| 2024 Q1 | -36.2 Million SEK | -5.73% |
| 2023 Q2 | -43.78 Million SEK | 25.06% |
| 2023 Q4 | -34.5 Million SEK | 7.45% |
| 2023 FY | - SEK | -62.3% |
| 2023 Q3 | -37.28 Million SEK | 14.84% |
| 2023 Q1 | -58.42 Million SEK | -87.15% |
| 2022 Q3 | -22.91 Million SEK | 12.07% |
| 2022 Q2 | -26.05 Million SEK | 7.42% |
| 2022 Q1 | -28.14 Million SEK | -27.76% |
| 2022 FY | - SEK | -294.75% |
| 2022 Q4 | -31.21 Million SEK | -36.25% |
| 2021 Q2 | -25.6 Million SEK | -32.46% |
| 2021 FY | - SEK | 162.36% |
| 2021 Q4 | -22.02 Million SEK | -117.97% |
| 2021 Q1 | -19.33 Million SEK | -2.52% |
| 2021 Q3 | 122.59 Million SEK | 578.76% |
| 2020 Q2 | -25.53 Million SEK | -37.98% |
| 2020 Q3 | -26.3 Million SEK | -2.98% |
| 2020 Q4 | -18.85 Million SEK | 28.3% |
| 2020 FY | - SEK | 4.07% |
| 2020 Q1 | -18.5 Million SEK | 26.03% |
| 2019 FY | - SEK | -28.15% |
| 2019 Q4 | -25.02 Million SEK | -19.49% |
| 2019 Q3 | -20.94 Million SEK | 29.84% |
| 2019 Q2 | -29.84 Million SEK | -74.54% |
| 2019 Q1 | -17.1 Million SEK | 3.72% |
| 2018 Q1 | -15.66 Million SEK | -21.31% |
| 2018 FY | - SEK | -32.1% |
| 2018 Q4 | -17.76 Million SEK | -12.9% |
| 2018 Q2 | -23.39 Million SEK | -49.33% |
| 2018 Q3 | -15.73 Million SEK | 32.75% |
| 2017 Q1 | -9.8 Million SEK | 32.5% |
| 2017 Q2 | -10.55 Million SEK | -7.66% |
| 2017 Q3 | -20.6 Million SEK | -95.23% |
| 2017 Q4 | -12.91 Million SEK | 37.3% |
| 2017 FY | - SEK | -20.11% |
| 2016 Q1 | -13.95 Million SEK | 0.0% |
| 2016 FY | - SEK | -67.81% |
| 2016 Q3 | -10.52 Million SEK | -56.52% |
| 2016 Q2 | -6.72 Million SEK | 51.8% |
| 2016 Q4 | -14.52 Million SEK | -37.91% |
| 2015 FY | - SEK | -442.04% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | -675.048% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 45.404% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 38.545% |
| Xintela AB (publ) | -53.47 Million SEK | -224.146% |
| Active Biotech AB (publ) | -43.88 Million SEK | -294.932% |
| Amniotics AB (publ) | -27.14 Million SEK | -538.559% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -1119.132% |
| BioArctic AB (publ) | 275.38 Million SEK | 162.938% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 52.876% |
| Camurus AB (publ) | 562.54 Million SEK | 130.811% |
| Cantargia AB (publ) | -284.31 Million SEK | 39.038% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -785.255% |
| CombiGene AB (publ) | -35.33 Million SEK | -390.502% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -23.055% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -914.51% |
| Genovis AB (publ.) | 64.57 Million SEK | 368.42% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -50.839% |
| Mendus AB (publ) | -97.84 Million SEK | -77.14% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -368.14% |
| Intervacc AB (publ) | -68.98 Million SEK | -151.267% |
| Kancera AB (publ) | -61.88 Million SEK | -180.056% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -547.142% |
| LIDDS AB (publ) | -39.67 Million SEK | -336.915% |
| Lipum AB (publ) | -37.11 Million SEK | -366.941% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -1331.956% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 651.917% |
| NextCell Pharma AB | -40.98 Million SEK | -322.895% |
| OncoZenge AB (publ) | 7.26 Million SEK | 2485.412% |
| Saniona AB (publ) | -69.69 Million SEK | -148.689% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -2.066% |
| Ziccum AB (publ) | -20.34 Million SEK | -752.05% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 8666300.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 27.056% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -8232.885% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -1190.477% |
| Corline Biomedical AB | -1.69 Million SEK | -10149.793% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -216.25% |
| Aptahem AB (publ) | -10 Million SEK | -1631.642% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 1600.771% |
| Fluicell AB (publ) | -25.91 Million SEK | -568.843% |
| Biovica International AB (publ) | -119.5 Million SEK | -45.034% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -310.487% |
| AcouSort AB (publ) | -16.7 Million SEK | -937.682% |
| Abliva AB (publ) | -93.6 Million SEK | -85.159% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 45.683% |
| 2cureX AB (publ) | -35.13 Million SEK | -393.295% |
| I-Tech AB | 30.34 Million SEK | 671.178% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 75.744% |
| Cyxone AB (publ) | -20.41 Million SEK | -749.045% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -69.174% |
| Biosergen AB | 228 Thousand SEK | 76119.298% |
| Nanologica AB (publ) | -62.11 Million SEK | -179.019% |
| SynAct Pharma AB | -222.7 Million SEK | 22.172% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -295.167% |
| BioInvent International AB (publ) | -312.7 Million SEK | 44.573% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 56117.039% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 412786.016% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 25.169% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -1866.802% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -59.66% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -1411.239% |